The financing supports VALANX's lead antibody-drug conjugate programme targeting LIV-1 in metastatic triple-negative breast cancer. Foundation Fournier-Majoie and FUJIFILM Corporation joined as new investors alongside existing backers. Ana Maricevic from Foundation Fournier-Majoie will join the company's Board of Directors.
About VALANX Biotech
A Vienna-based MedTech startup developing the GoldenSite platform for site-specific protein conjugation, with a lead antibody-drug conjugate program for metastatic triple-negative breast cancer.
Vienna, Austria
Read Company ProfileFrequently Asked Questions
What type of funding round did VALANX Biotech raise?
VALANX Biotech raised a series-c round.
How much did VALANX Biotech raise in its series-c?
VALANX Biotech raised $3,000,000 EUR in its series-c.
When did VALANX Biotech raise its series-c?
VALANX Biotech raised its series-c on 2026-03-12.
Who invested in VALANX Biotech's series-c?
The investors in VALANX Biotech's series-c are: Foundation Fournier-Majoie, FUJIFILM Corporation, Xista Science Ventures, tecnet equity, Urs Spitz, SkyGene.
How will VALANX Biotech use the funds from its series-c?
VALANX Biotech plans to use the funds for: Advance the preclinical development of VLX-ADC-001, Complete candidate selection by June 2026, Support GMP readiness, Prepare the technology for future clinical development, Pursue potential partnerships related to the GoldenSite platform.